Proteologix’s lineup includes PX128, a bispecific antibody that targets both IL-13 plus TSLP. PX128 is poised to advance into phase 1 development for the treatment of moderate to severe atopic dermatitis and asthma.

Bayer Begins Phase I Trial of 225Ac-PSMA-Trillium Targeted Radionuclide Therapy for Advanced Metastatic Prostate Cancer.

The U.S. FDA has approved Bristol Myers Squibb's CAR T cell therapy Breyanzi for treating relapsed or refractory follicular lymphoma.

Genentech Announces Favorable Phase Ib Outcomes for Dual GLP-1/GIP Receptor Agonist CT-388 in Obesity Patients.

The trial involves the use of IMUNON’s IMNN-001, a DNA-based immunotherapy, alongside bevacizumab, in patients with this condition.

Monopar Therapeutics is advancing its Phase 1 dosimetry clinical trial for MNPR-101-Zr, a potential treatment for advanced cancers.

ATHEx Biotech has received approval from the FDA to commence clinical trials for ATX-01, a pioneering microRNA-based treatment for Myotonic Dystrophy Type 1 (DM1).

ImmPACT Bio has received an $8 million grant from the California Institute for Regenerative Medicine (CIRM) to support the Phase 1b/2 study of IMPT-514, a novel CAR T-cell therapy.

Skyhawk Therapeutics has made significant progress with its innovative drug candidate, SKY-0515, which is engineered to be an RNA splicing modifier.

Tonix Pharmaceuticals Holding Corp. has finished the clinical phase of its Phase 1 trial for TNX-1500, a humanized monoclonal antibody (mAb) designed to prevent organ transplant rejection and treat autoimmune diseases.

PharmAust Limited has reported that its drug monepantel (MPL) has outperformed the FDA-approved Relyvrio® in terms of safety and tolerability.

S.BIOMEDICS Co., Ltd., a leading company in stem cell therapy, has recently completed a Phase 1/2a clinical trial involving the transplantation of TED-A9 cells into the brains of 12 Parkinson's disease patients.